Tag Archive for: Dr. Peter Haug

From 18 to 21 November we attended MEDICA 2019, in Düsseldorf. We were at the joint booth for the industry association medways e.V. in the world’s largest trade fair for the medical sector.

Record Number of Exhibitors and Visitors

This year the trade fair broke its own record once again with around 5,500 exhibitors and 121,000 visitors. About 170 different countries gathered at the No. 1 platform for international business. Many visitors came by oncgnostics’ booth to learn about our latest developments.

“For us, MEDICA is the most important trade fair of the year. This is where the industry comes together, where we make and maintain important contacts. As exhibitors, we are able to introduce ourselves, and we are very happy to use our own booth for meetings. At the same time, it is always worth taking a tour around the fair to get up to date,” says Dr Alfred Hansel, oncgnostics’ Managing Director, describing his impressions.


Dr. Peter Haug

Simultaneously to MEDICA, COMPAMED, the trade fair for medical suppliers, took place. Our Head of Business Development & Licensing, Dr Peter Haug, accepted the invitation of IVAM, the professional association for microtechnology, and gave a sales pitch at the High-tech for Medical Devices forum.

“Oncgnostics GmbH is not only a manufacturer of reliable and innovative devices for cancer diagnostics: It is also of interest as a development partner to other pharmaceutical and diagnostic companies that would like to develop reliable tests based on epigenetic markers for new indications with us. Moreover, thanks to our strategic partnership with GeneoDx, a subsidiary of the Chinese SINOPHARM Group, we are also able to offer high-volume orders,” summarises Dr Peter Haug.

Oncgnostics GmbH is greatly honoured to have been selected by EURONEXT for the TechShare programme. We will be participating in top-class workshops and coaching sessions for half a year.

High-quality Coaching for Start-ups

As one of eleven German start-ups in the medical and biotech sectors, we will have the opportunity to broaden our horizons over the next six months. We will learn how a potential IPO should be prepared, and for which companies it can be useful. In addition, we can look forward to high-quality coaching directly at our premises in Jena. With the acquired knowledge, we will be able to constantly work on and strengthen our company strategy.

Learning from the Success of Others

Euronext TechShare Campus 2019 Rotterdam | photo: Robert Tjalondo © | www.rockinpictures.com

Dr Peter Haug, Head of Business Development & Licensing at oncgnostics, was present at the Kick-off Campus Erasmus Centre for Entrepreneurship at the University of Rotterdam. The extensive programme was supported by top speakers such as Onno van de Stolpe, CEO and founder of Galapagos NV. The Belgian drug research company was founded in 1999 and successfully went public just six years later: ‘It is very inspiring to hear about the success stories of former start-ups,’ says Dr Peter Haug, describing van de Stolpe’s presentation. ‘In addition, EURONEXT has put together a fascinating selection of high-profile European start-ups. I already knew some of them before, and look forward to networking with the others, all of whom are facing similar next steps and challenges as we are at oncgnostics GmbH.’

After the kick-off in Rotterdam with around 150 international participants, they will continue in different groups. Oncgnostics GmbH will participate in four workshops in Munich, together with six other companies from the Biotech and Medtech sectors. Next spring, all participants will meet in Lisbon for the closing event.